These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 36176438

  • 1. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.
    Lee YC, Dong YH, Yang WS, Wu LC, Lin JW, Chang CH.
    Front Pharmacol; 2022; 13():869804. PubMed ID: 36176438
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

  • 5. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM.
    Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
    [Abstract] [Full Text] [Related]

  • 6. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK, Bhatt DL, Montvida O.
    Eur Heart J; 2021 May 07; 42(18):1728-1738. PubMed ID: 33289789
    [Abstract] [Full Text] [Related]

  • 7. Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.
    Bea S, Lee H, Park S, Cho YM, Choi WS, Bykov K, Shin JY.
    Clin Pharmacol Ther; 2024 May 07; 115(5):1132-1140. PubMed ID: 38284421
    [Abstract] [Full Text] [Related]

  • 8. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 9. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2235995. PubMed ID: 36219443
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M, Sattar N, Miftaraj M, Ekelund J, Franzén S, Svensson AM, Eliasson B.
    Cardiovasc Diabetol; 2021 Mar 22; 20(1):67. PubMed ID: 33752680
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
    Deng S, Zhao H, Chai S, Sun Y, Shen P, Lin H, Zhan S.
    Front Endocrinol (Lausanne); 2024 Mar 22; 15():1369908. PubMed ID: 38803473
    [Abstract] [Full Text] [Related]

  • 15. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM, Te Groen M, Rovers MM, Tack CJ.
    Br J Clin Pharmacol; 2016 Jul 22; 82(1):301-14. PubMed ID: 26935973
    [Abstract] [Full Text] [Related]

  • 16. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
    Monda VM, Voci C, Strollo F, Passaro A, Greco S, Monesi M, Bigoni R, Porcellati F, Piani D, Satta E, Gentile S.
    Diabetes Ther; 2023 Dec 22; 14(12):2127-2142. PubMed ID: 37801224
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.
    BMC Endocr Disord; 2022 Sep 29; 22(1):241. PubMed ID: 36175881
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Sep 29; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.